SGA
TEVA icon

Strategic Global Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Strategic Global Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,195
Closed -$206K – 157
2025
Q3 		$206K Sell
10,195
-93
-0.9% -$1.63K 0.03% 133
2025
Q2 		$172K Buy
+10,288
New +$166K 0.03% 139
2019
Q3 		– Sell
-87,712
Closed -$810K – 163
2019
Q2 		$810K Sell
87,712
-535,388
-86% -$6.46M 0.17% 113
2019
Q1 		$9.77M Buy
623,100
+10,504
+2% +$185K 2.06% 8
2018
Q4 		$9.45M Buy
612,596
+269,306
+78% +$5.52M 3.38% 7
2018
Q3 		$7.39M Buy
+343,290
New +$7.97M 2.24% 9
2017
Q1 		– Sell
-6,450
Closed -$234K – 173
2016
Q4 		$234K Hold
6,450
– – 0.09% 146
2016
Q3 		$323K Hold
6,450
– – 0.12% 133
2016
Q2 		$324K Hold
6,450
– – 0.12% 131
2016
Q1 		$345K Buy
6,450
+1,298
+25% +$76.2K 0.15% 117
2015
Q4 		$338K Buy
5,152
+15
+0.3% +$927 0.14% 113
2015
Q3 		$290K Sell
5,137
-2,918
-36% -$189K 0.14% 105
2015
Q2 		$476K Buy
8,055
+4,519
+128% +$279K 0.28% 84
2015
Q1 		$220K Hold
3,536
– – 0.16% 123
2014
Q4 		$204K Buy
+3,536
New +$197K 0.18% 127

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Strategic Global Advisors's TEVA Position: Q4 2025 in Review

Strategic Global Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 10,195 shares — an estimated $206K sold.

Strategic Global Advisors first reported a position in TEVA in Q4 2014 and held it in 15 quarters. The position peaked at $9.77M in Q1 2019. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Strategic Global Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Strategic Global Advisors sold 10,195 Teva Pharmaceuticals shares in Q4 2025, an estimated $206K.
  • Strategic Global Advisors first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 15 quarters.
  • Strategic Global Advisors's Teva Pharmaceuticals position peaked at $9.77M in Q1 2019.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Strategic Global Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.